Principal Scientist Amgen Inc. Thousand Oaks, California, United States
The goal of this session is to bring together kidney subject matter experts across sectors to share novel research on generating predictive tools (i.e., in vitro assays, biomarkers) as well as highlighting strategies used to investigate DIKI within drug discovery and preclinical evaluation. As experts in their field, the speakers offer critical perspectives on addressing drug-induced kidney toxicity and the inclusion of toxicological parameters that are essential for improving safety assessment of molecules with potential renal safety liabilities. This session highlights current methodologies for kidney toxicity evaluation and implementation of safety-by-design strategies to help select drug candidates with favorable kidney safety profiles. This introduction will provide high-level background focused on DIKI and the current challenges facing the field of kidney toxicology.
